Accolade, Inc. (NASDAQ: ACCD) Stock Competitors & Peer Comparison

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, GEHC has a market cap of 32.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while GEHC trades at $72.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas GEHC's P/E ratio is 15.74. In terms of profitability, ACCD's ROE is -0.22%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ACCD is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check GEHC's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas GEHCV's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, ACCD is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check GEHCV's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, BTSG has a market cap of 12.3B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BTSG trades at $62.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas BTSG's P/E ratio is 50.35. In terms of profitability, ACCD's ROE is -0.22%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, ACCD is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BTSG's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, TEM has a market cap of 9.1B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TEM trades at $54.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas TEM's P/E ratio is -104.10. In terms of profitability, ACCD's ROE is -0.22%, compared to TEM's ROE of -0.55%. Regarding short-term risk, ACCD is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TEM's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SGFY's P/E ratio is 70.91. In terms of profitability, ACCD's ROE is -0.22%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, ACCD is less volatile compared to SGFY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SGFY's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, HQY has a market cap of 8.7B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HQY trades at $107.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas HQY's P/E ratio is 24.45. In terms of profitability, ACCD's ROE is -0.22%, compared to HQY's ROE of +0.11%. Regarding short-term risk, ACCD is less volatile compared to HQY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HQY's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, HNGE has a market cap of 6.9B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HNGE trades at $89.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas HNGE's P/E ratio is 47.81. In terms of profitability, ACCD's ROE is -0.22%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, ACCD is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HNGE's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, TXG has a market cap of 6.6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TXG trades at $54.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas TXG's P/E ratio is -306.06. In terms of profitability, ACCD's ROE is -0.22%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ACCD is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TXG's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas RCM's P/E ratio is -102.21. In terms of profitability, ACCD's ROE is -0.22%, compared to RCM's ROE of +0.00%. Regarding short-term risk, ACCD is similarly volatile compared to RCM. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check RCM's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, DOCS has a market cap of 5.1B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while DOCS trades at $25.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas DOCS's P/E ratio is 17.91. In terms of profitability, ACCD's ROE is -0.22%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check DOCS's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, WAY has a market cap of 4.6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WAY trades at $24.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas WAY's P/E ratio is 16.05. In terms of profitability, ACCD's ROE is -0.22%, compared to WAY's ROE of +0.04%. Regarding short-term risk, ACCD is less volatile compared to WAY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check WAY's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ONEM's P/E ratio is -7.77. In terms of profitability, ACCD's ROE is -0.22%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, ACCD is less volatile compared to ONEM. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ONEM's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PRVA trades at $22.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas PRVA's P/E ratio is 106.90. In terms of profitability, ACCD's ROE is -0.22%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, ACCD is less volatile compared to PRVA. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PRVA's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HTFL trades at $29.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas HTFL's P/E ratio is -14.34. In terms of profitability, ACCD's ROE is -0.22%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, ACCD is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HTFL's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WGS trades at $77.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas WGS's P/E ratio is 214.11. In terms of profitability, ACCD's ROE is -0.22%, compared to WGS's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check WGS's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, PGNY has a market cap of 2.2B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PGNY trades at $28.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas PGNY's P/E ratio is 20.36. In terms of profitability, ACCD's ROE is -0.22%, compared to PGNY's ROE of +0.16%. Regarding short-term risk, ACCD is less volatile compared to PGNY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PGNY's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, WGSWW has a market cap of 1.8B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas WGSWW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, ACCD is similarly volatile compared to WGSWW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check WGSWW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas NXGN's P/E ratio is -266.00. In terms of profitability, ACCD's ROE is -0.22%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, ACCD is less volatile compared to NXGN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check NXGN's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while OMDA trades at $24.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas OMDA's P/E ratio is 338.14. In terms of profitability, ACCD's ROE is -0.22%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check OMDA's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas AGTI's P/E ratio is -71.79. In terms of profitability, ACCD's ROE is -0.22%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to AGTI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AGTI's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TDOC trades at $7.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas TDOC's P/E ratio is -7.92. In terms of profitability, ACCD's ROE is -0.22%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, ACCD is less volatile compared to TDOC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TDOC's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CERT trades at $8.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CERT's P/E ratio is 20.50. In terms of profitability, ACCD's ROE is -0.22%, compared to CERT's ROE of -0.07%. Regarding short-term risk, ACCD is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CERT's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, GDRX has a market cap of 1.3B. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while GDRX trades at $3.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas GDRX's P/E ratio is 11.50. In terms of profitability, ACCD's ROE is -0.22%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check GDRX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CCLDO's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, ACCD is similarly volatile compared to CCLDO. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check CCLDO's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, HSTM has a market cap of 839.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HSTM trades at $29.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas HSTM's P/E ratio is 35.46. In terms of profitability, ACCD's ROE is -0.22%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, ACCD is less volatile compared to HSTM. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HSTM's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, PHR has a market cap of 773M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PHR trades at $12.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas PHR's P/E ratio is 44.66. In terms of profitability, ACCD's ROE is -0.22%, compared to PHR's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to PHR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PHR's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, ACCD is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MPLN-WT's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CTEV has a market cap of 546.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CTEV trades at $34.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CTEV's P/E ratio is -2.46. In terms of profitability, ACCD's ROE is -0.22%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, ACCD is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CTEV's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SOPH has a market cap of 537.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SOPH trades at $7.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SOPH's P/E ratio is -6.95. In terms of profitability, ACCD's ROE is -0.22%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, ACCD is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SOPH's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SHCR's P/E ratio is -3.76. In terms of profitability, ACCD's ROE is -0.22%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, ACCD is less volatile compared to SHCR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SHCR's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, NRC has a market cap of 458.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while NRC trades at $20.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas NRC's P/E ratio is 24.80. In terms of profitability, ACCD's ROE is -0.22%, compared to NRC's ROE of +0.48%. Regarding short-term risk, ACCD is less volatile compared to NRC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check NRC's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, EVH has a market cap of 446M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while EVH trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas EVH's P/E ratio is 30.50. In terms of profitability, ACCD's ROE is -0.22%, compared to EVH's ROE of -0.99%. Regarding short-term risk, ACCD is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check EVH's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, ACCD's ROE is -0.22%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, ACCD is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SLGCW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SLGC's P/E ratio is -3.04. In terms of profitability, ACCD's ROE is -0.22%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, ACCD is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SLGC's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas TBRG's P/E ratio is 9.37. In terms of profitability, ACCD's ROE is -0.22%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to TBRG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TBRG's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MPLN's P/E ratio is -0.23. In terms of profitability, ACCD's ROE is -0.22%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, ACCD is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MPLN's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SY has a market cap of 286M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SY trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SY's P/E ratio is -6.61. In terms of profitability, ACCD's ROE is -0.22%, compared to SY's ROE of -0.16%. Regarding short-term risk, ACCD is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SY's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas TRHC's P/E ratio is -4.27. In terms of profitability, ACCD's ROE is -0.22%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, ACCD is less volatile compared to TRHC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check TRHC's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SMFR's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SMFR's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SPOK has a market cap of 240.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SPOK trades at $11.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SPOK's P/E ratio is 19.20. In terms of profitability, ACCD's ROE is -0.22%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, ACCD is less volatile compared to SPOK. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SPOK's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, AMWL has a market cap of 228.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AMWL trades at $13.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas AMWL's P/E ratio is -3.04. In terms of profitability, ACCD's ROE is -0.22%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, ACCD is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AMWL's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CPSI's P/E ratio is -183.80. In terms of profitability, ACCD's ROE is -0.22%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, ACCD is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CPSI's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, OPRX has a market cap of 132.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while OPRX trades at $7.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas OPRX's P/E ratio is 6.50. In terms of profitability, ACCD's ROE is -0.22%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, ACCD is less volatile compared to OPRX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check OPRX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, HCAT has a market cap of 127.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HCAT trades at $1.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas HCAT's P/E ratio is 8.65. In terms of profitability, ACCD's ROE is -0.22%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, ACCD is less volatile compared to HCAT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HCAT's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas AUGX's P/E ratio is -4.99. In terms of profitability, ACCD's ROE is -0.22%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, ACCD is less volatile compared to AUGX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AUGX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLD has a market cap of 111.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CCLD trades at $2.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CCLD's P/E ratio is 10.12. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CCLD's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, DH has a market cap of 75.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while DH trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas DH's P/E ratio is 2.74. In terms of profitability, ACCD's ROE is -0.22%, compared to DH's ROE of -0.67%. Regarding short-term risk, ACCD is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check DH's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, WORX has a market cap of 72.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while WORX trades at $4.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas WORX's P/E ratio is -5.29. In terms of profitability, ACCD's ROE is -0.22%, compared to WORX's ROE of -0.65%. Regarding short-term risk, ACCD is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check WORX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas FORA's P/E ratio is -24.11. In terms of profitability, ACCD's ROE is -0.22%, compared to FORA's ROE of -0.17%. Regarding short-term risk, ACCD is similarly volatile compared to FORA. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check FORA's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CCLDP's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to CCLDP. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CCLDP's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONMDW has a market cap of 37M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ONMDW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ONMDW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, ACCD is similarly volatile compared to ONMDW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check ONMDW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ONMD has a market cap of 35.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ONMD trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ONMD's P/E ratio is -4.16. In terms of profitability, ACCD's ROE is -0.22%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, ACCD is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ONMD's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SNCE's P/E ratio is -0.27. In terms of profitability, ACCD's ROE is -0.22%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, ACCD is less volatile compared to SNCE. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SNCE's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas AKLI's P/E ratio is -0.71. In terms of profitability, ACCD's ROE is -0.22%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, ACCD is less volatile compared to AKLI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AKLI's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SHLT's P/E ratio is -3.87. In terms of profitability, ACCD's ROE is -0.22%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, ACCD is similarly volatile compared to SHLT. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check SHLT's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, ACCD is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SHCRW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas STRM's P/E ratio is -2.40. In terms of profitability, ACCD's ROE is -0.22%, compared to STRM's ROE of -0.65%. Regarding short-term risk, ACCD is similarly volatile compared to STRM. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check STRM's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas RNLX's P/E ratio is -0.33. In terms of profitability, ACCD's ROE is -0.22%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, ACCD is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check RNLX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas LIFW's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, ACCD is similarly volatile compared to LIFW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check LIFW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas BBLN's P/E ratio is -0.04. In terms of profitability, ACCD's ROE is -0.22%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, ACCD is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BBLN's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, BEATW has a market cap of 11.7M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BEATW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas BEATW's P/E ratio is -0.03. In terms of profitability, ACCD's ROE is -0.22%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, ACCD is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BEATW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ETAO's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, ACCD is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ETAO's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MGRX has a market cap of 8.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MGRX trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MGRX's P/E ratio is -0.36. In terms of profitability, ACCD's ROE is -0.22%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, ACCD is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MGRX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, BFRG has a market cap of 6.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while BFRG trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas BFRG's P/E ratio is -1.09. In terms of profitability, ACCD's ROE is -0.22%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, ACCD is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check BFRG's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SCNX has a market cap of 5.9M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SCNX trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SCNX's P/E ratio is -0.15. In terms of profitability, ACCD's ROE is -0.22%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, ACCD is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SCNX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas UPH's P/E ratio is -0.07. In terms of profitability, ACCD's ROE is -0.22%, compared to UPH's ROE of -1.05%. Regarding short-term risk, ACCD is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check UPH's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, ACCD is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check UPH-WT's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas PEARW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PEARW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas PEAR's P/E ratio is -0.08. In terms of profitability, ACCD's ROE is -0.22%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check PEAR's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas OTRK's P/E ratio is -0.02. In terms of profitability, ACCD's ROE is -0.22%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, ACCD is similarly volatile compared to OTRK. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check OTRK's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CMAX's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, ACCD is similarly volatile compared to CMAX. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check CMAX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, HCTI has a market cap of 1.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while HCTI trades at $1.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas HCTI's P/E ratio is -0.16. In terms of profitability, ACCD's ROE is -0.22%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, ACCD is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check HCTI's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, VSEEW has a market cap of 1.4M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, ACCD's ROE is -0.22%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, ACCD is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check VSEEW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, ACCD is similarly volatile compared to LIFWZ. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check LIFWZ's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ACON has a market cap of 1.2M. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ACON trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ACON's P/E ratio is -0.25. In terms of profitability, ACCD's ROE is -0.22%, compared to ACON's ROE of -0.59%. Regarding short-term risk, ACCD is less volatile compared to ACON. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ACON's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, EUDAW has a market cap of 952.7K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while EUDAW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, ACCD's ROE is -0.22%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, ACCD is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check EUDAW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, VSEE has a market cap of 816.5K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while VSEE trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas VSEE's P/E ratio is -0.10. In terms of profitability, ACCD's ROE is -0.22%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, ACCD is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check VSEE's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, ACCD is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MSPRZ's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas KERN's P/E ratio is -0.01. In terms of profitability, ACCD's ROE is -0.22%, compared to KERN's ROE of -0.20%. Regarding short-term risk, ACCD is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check KERN's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas KERNW's P/E ratio is -0.00. In terms of profitability, ACCD's ROE is -0.22%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, ACCD is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check KERNW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas LIFWW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, ACCD is similarly volatile compared to LIFWW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check LIFWW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ZCMD has a market cap of 37.5K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ZCMD trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ZCMD's P/E ratio is -0.04. In terms of profitability, ACCD's ROE is -0.22%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, ACCD is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check ZCMD's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CMAXW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, ACCD is similarly volatile compared to CMAXW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check CMAXW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, ACONW has a market cap of 13.2K. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while ACONW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas ACONW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, ACCD is similarly volatile compared to ACONW. This indicates similar risk in terms of short-term price fluctuations for ACCD.Check ACONW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, NH has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas NH's P/E ratio is -0.12. In terms of profitability, ACCD's ROE is -0.22%, compared to NH's ROE of +0.35%. Regarding short-term risk, ACCD is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check NH's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MTBCO's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to MTBCO. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MTBCO's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MSPRV's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MSPRV's ROE of N/A. Regarding short-term risk, ACCD is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MSPRV's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CERN has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CERN's P/E ratio is 55.84. In terms of profitability, ACCD's ROE is -0.22%, compared to CERN's ROE of +0.14%. Regarding short-term risk, ACCD is less volatile compared to CERN. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CERN's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas KURIU's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, ACCD is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check KURIU's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CNVY's P/E ratio is -71.50. In terms of profitability, ACCD's ROE is -0.22%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, ACCD is less volatile compared to CNVY. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CNVY's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MTBC's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, ACCD is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MTBC's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CSLT's P/E ratio is -37.27. In terms of profitability, ACCD's ROE is -0.22%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, ACCD is less volatile compared to CSLT. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CSLT's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, IMS has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas IMS's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to IMS's ROE of +0.27%. Regarding short-term risk, ACCD is less volatile compared to IMS. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check IMS's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas NAVA's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, ACCD is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for ACCD.Check NAVA's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas AFFX's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, ACCD is less volatile compared to AFFX. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check AFFX's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CHNGU's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, ACCD is less volatile compared to CHNGU. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CHNGU's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas SMFRW's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, ACCD is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check SMFRW's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas CHNG's P/E ratio is -152.72. In terms of profitability, ACCD's ROE is -0.22%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, ACCD is less volatile compared to CHNG. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check CHNG's competition here

Accolade, Inc. (NASDAQ: ACCD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACCD stands at 575.6M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, ACCD is priced at $7.02 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACCD currently has a P/E ratio of -3.08, whereas MTBCP's P/E ratio is N/A. In terms of profitability, ACCD's ROE is -0.22%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, ACCD is less volatile compared to MTBCP. This indicates lower risk in terms of short-term price fluctuations for ACCD.Check MTBCP's competition here